Current Edition


In a first, FDA approves an ‘interchangeable’ biosimilar for diabetes

The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn’t materialized in the U.S. in the way …

Continue Reading →

Lupin, Mylan to commercialize Enbrel Biosimilar

Under the terms of the agreement, Lupin will receive an up-front payment of $15 million. Pharma major Lupin Limited and global pharmaceutical company Mylan have …

Continue Reading →